Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database
Purpose: To develop the clinical calculator for mortality of patients with metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database. Materials and Methods: Data from 1,115 patients with mRCC treated in 4 hospitals joining KRoCS between 1993 and 2016 were pooled....
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Urological Association
2020-05-01
|
| Series: | Investigative and Clinical Urology |
| Subjects: | |
| Online Access: | https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-260.pdf |
| _version_ | 1818843331995631616 |
|---|---|
| author | Jae Young Park Bum Sik Tae Chang Wook Jeong Cheryn Song Seong Il Seo Sung Kyu Hong Jinsoo Chung Sung-Hoo Hong Eu Chang Hwang Cheol Kwak Ill Young Seo Suyeon Park Chanwang Park |
| author_facet | Jae Young Park Bum Sik Tae Chang Wook Jeong Cheryn Song Seong Il Seo Sung Kyu Hong Jinsoo Chung Sung-Hoo Hong Eu Chang Hwang Cheol Kwak Ill Young Seo Suyeon Park Chanwang Park |
| author_sort | Jae Young Park |
| collection | DOAJ |
| description | Purpose: To develop the clinical calculator for mortality of patients with metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database. Materials and Methods: Data from 1,115 patients with mRCC treated in 4 hospitals joining KRoCS between 1993 and 2016 were pooled. Five-year survival rates were calculated using Kaplan–Meier curve. A clinical calculator for 5-year mortality was developed using multivariable logistic regression analysis and validated externally using dataset including 916 patients from 4 other hospitals. Results: Overall survival rates and cancer specific survival rate at 5 years were 28.5% and 29.4%, respectively. Among baseline factors, increased neutrophil-lymphocyte ratio (≥4), synchronous metastasis, low albumin (<3.0 g/dL), and low hemoglobin (<lower limit of normal: male, 13 g/dL; female, 11.5 g/dL) were the significant factors in 5-year mortality. Good internal validity was demonstrated with area under the curve estimates being 0.774 at 5-year mortality calculation and the calibration plot. In the external validation, 758 (82.8%) died by 5 years among these patients, with the average model-predicted rate of 72.9%. Conclusions: A clinical calculator has been developed to quantify the risk of death for individual patients after treatment of mRCC. This tool may be useful for patients or their guardians who want to know their prognosis and to identify patients requiring aggressive therapy and additional supportive measures during and after treatment. |
| first_indexed | 2024-12-19T04:56:11Z |
| format | Article |
| id | doaj.art-85c01b4e5af044998ea5bdef0cf55292 |
| institution | Directory Open Access Journal |
| issn | 2466-0493 2466-054X |
| language | English |
| last_indexed | 2024-12-19T04:56:11Z |
| publishDate | 2020-05-01 |
| publisher | Korean Urological Association |
| record_format | Article |
| series | Investigative and Clinical Urology |
| spelling | doaj.art-85c01b4e5af044998ea5bdef0cf552922022-12-21T20:35:14ZengKorean Urological AssociationInvestigative and Clinical Urology2466-04932466-054X2020-05-0161326026810.4111/icu.2020.61.3.260Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group databaseJae Young Park0https://orcid.org/0000-0002-6664-6846Bum Sik Tae1https://orcid.org/0000-0003-2963-7366Chang Wook Jeong 2https://orcid.org/0000-0002-2200-5019Cheryn Song 3https://orcid.org/0000-0002-1823-4281Seong Il Seo 4https://orcid.org/0000-0002-9792-7798Sung Kyu Hong 5https://orcid.org/0000-0002-8344-6774Jinsoo Chung 6https://orcid.org/0000-0003-2251-5331Sung-Hoo Hong 7https://orcid.org/0000-0002-1952-4010Eu Chang Hwang 8https://orcid.org/0000-0002-2031-124XCheol Kwak 9https://orcid.org/0000-0002-1987-2111Ill Young Seo 10https://orcid.org/0000-0003-2061-8214Suyeon Park11https://orcid.org/0000-0002-6391-557XChanwang Park 12https://orcid.org/0000-0001-5099-5550Department of Urology, Korea University Ansan Hospital, Ansan, Korea.Department of Urology, Korea University Ansan Hospital, Ansan, Korea.Department of Urology, Seoul National University Hospital, Seoul, Korea.Department of Urology, Asan Medical Center, Seoul, Korea.Department of Urology, Samsung Medical Center, Seoul, Korea.Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea.Department of Urology, National Cancer Center, Goyang, Korea.Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.Department of Urology, Chonnam National University Hwasun Hospital, Hwasun, Korea.Department of Urology, Seoul National University Hospital, Seoul, Korea.Department of Urology, Wonkwang University Hospital, Iksan, Korea.Department of Biostatistics, Soonchunhyang University Seoul Hospital, Seoul, Korea.Anesthesia Consultants of Indianapolis, Indianapolis, IN, USA.Purpose: To develop the clinical calculator for mortality of patients with metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database. Materials and Methods: Data from 1,115 patients with mRCC treated in 4 hospitals joining KRoCS between 1993 and 2016 were pooled. Five-year survival rates were calculated using Kaplan–Meier curve. A clinical calculator for 5-year mortality was developed using multivariable logistic regression analysis and validated externally using dataset including 916 patients from 4 other hospitals. Results: Overall survival rates and cancer specific survival rate at 5 years were 28.5% and 29.4%, respectively. Among baseline factors, increased neutrophil-lymphocyte ratio (≥4), synchronous metastasis, low albumin (<3.0 g/dL), and low hemoglobin (<lower limit of normal: male, 13 g/dL; female, 11.5 g/dL) were the significant factors in 5-year mortality. Good internal validity was demonstrated with area under the curve estimates being 0.774 at 5-year mortality calculation and the calibration plot. In the external validation, 758 (82.8%) died by 5 years among these patients, with the average model-predicted rate of 72.9%. Conclusions: A clinical calculator has been developed to quantify the risk of death for individual patients after treatment of mRCC. This tool may be useful for patients or their guardians who want to know their prognosis and to identify patients requiring aggressive therapy and additional supportive measures during and after treatment.https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-260.pdfcarcinomarenal cellmortalityprognosis |
| spellingShingle | Jae Young Park Bum Sik Tae Chang Wook Jeong Cheryn Song Seong Il Seo Sung Kyu Hong Jinsoo Chung Sung-Hoo Hong Eu Chang Hwang Cheol Kwak Ill Young Seo Suyeon Park Chanwang Park Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database Investigative and Clinical Urology carcinoma renal cell mortality prognosis |
| title | Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
| title_full | Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
| title_fullStr | Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
| title_full_unstemmed | Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
| title_short | Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
| title_sort | development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma an analysis of patients from korean renal cancer study group database |
| topic | carcinoma renal cell mortality prognosis |
| url | https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-260.pdf |
| work_keys_str_mv | AT jaeyoungpark developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT bumsiktae developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT changwookjeong developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT cherynsong developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT seongilseo developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT sungkyuhong developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT jinsoochung developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT sunghoohong developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT euchanghwang developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT cheolkwak developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT illyoungseo developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT suyeonpark developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT chanwangpark developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase |